Clinical Trial Update: Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for AT7519M alone and in combination with bortezomib in previously treated multiple myeloma (Phase 1/Phase 2; completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AT7519M
• Bortezomib (bortezomib)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED